skip to content
Costs and Benefits of Prenatal Screening For Cystic Fibrosis Preview this item
ClosePreview this item
Checking...

Costs and Benefits of Prenatal Screening For Cystic Fibrosis

Author: Joseph P Fenerty; Alan M Garber; National Bureau of Economic Research.
Publisher: Cambridge, Mass. : National Bureau of Economic Research, 1988.
Series: Working paper series (National Bureau of Economic Research), no. w2749.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Newly-developed genetic tests based on restriction fragment length polymorphisms (RFLPs) promise to facilitate the early detection of genetic diseases. Several such tests are now available for the prenatal detection of cystic fibrosis (CF), a common and costly disease. The tests for CF are currently limited to prenatal diagnosis in siblings of a victim of CF. Direct gene probe tests, which have yet to be developed  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Additional Physical Format: Print version:
Fenerty, Joseph P.
Costs and benefits of prenatal screening for cystic fibrosis.
Cambridge, MA : National Bureau of Economic Research, [1988]
(OCoLC)18994426
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Joseph P Fenerty; Alan M Garber; National Bureau of Economic Research.
OCLC Number: 756572045
Description: 1 online resource.
Series Title: Working paper series (National Bureau of Economic Research), no. w2749.
Responsibility: Alan M. Garber, Joseph P. Fenerty.

Abstract:

Newly-developed genetic tests based on restriction fragment length polymorphisms (RFLPs) promise to facilitate the early detection of genetic diseases. Several such tests are now available for the prenatal detection of cystic fibrosis (CF), a common and costly disease. The tests for CF are currently limited to prenatal diagnosis in siblings of a victim of CF. Direct gene probe tests, which have yet to be developed for CF, would be applicable even in families that have not already borne a child with the disease. We examine the costs and benefits of prenatal testing for cystic fibrosis using existing RFLP-based tests and using a hypothetical direct gene probe test. We find that even an expensive RAPbased testing program produces substantial net benefits, because it is applied in pregnancies in which the risk of CF is 25%. If a direct gene probe test is applied in all pregnancies, it will need to be much less expensive to generate net benefits, and it will lead to the abortion of many normal fetuses unless it is highly specific. Because these new tests are likely to generate substantial savings in medical expenditures and to increase lifetime earnings, parents of CF-affected children may be subjected to strong pressures to participate in prenatal testing programs and to abort fetuses that test positive. It is imperative that the ethical dilemmas arising from this promising screening test be discussed openly before it becomes widely available.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.

Similar Items

Related Subjects:(2)

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/756572045> # Costs and Benefits of Prenatal Screening For Cystic Fibrosis
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "756572045" ;
    library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/19352747#Place/cambridge_mass> ; # Cambridge, Mass.
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mau> ;
    schema:about <http://id.worldcat.org/fast/886186> ; # Cystic fibrosis
    schema:about <http://id.worldcat.org/fast/1075465> ; # Prenatal diagnosis
    schema:bookFormat schema:EBook ;
    schema:contributor <http://viaf.org/viaf/38000528> ; # Alan M. Garber
    schema:contributor <http://viaf.org/viaf/211123975> ; # Joseph P. Fenerty
    schema:contributor <http://viaf.org/viaf/135446122> ; # National Bureau of Economic Research.
    schema:datePublished "1988" ;
    schema:description "Newly-developed genetic tests based on restriction fragment length polymorphisms (RFLPs) promise to facilitate the early detection of genetic diseases. Several such tests are now available for the prenatal detection of cystic fibrosis (CF), a common and costly disease. The tests for CF are currently limited to prenatal diagnosis in siblings of a victim of CF. Direct gene probe tests, which have yet to be developed for CF, would be applicable even in families that have not already borne a child with the disease. We examine the costs and benefits of prenatal testing for cystic fibrosis using existing RFLP-based tests and using a hypothetical direct gene probe test. We find that even an expensive RAPbased testing program produces substantial net benefits, because it is applied in pregnancies in which the risk of CF is 25%. If a direct gene probe test is applied in all pregnancies, it will need to be much less expensive to generate net benefits, and it will lead to the abortion of many normal fetuses unless it is highly specific. Because these new tests are likely to generate substantial savings in medical expenditures and to increase lifetime earnings, parents of CF-affected children may be subjected to strong pressures to participate in prenatal testing programs and to abort fetuses that test positive. It is imperative that the ethical dilemmas arising from this promising screening test be discussed openly before it becomes widely available."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/19352747> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/19352747#Series/nber_working_paper_series> ; # NBER working paper series ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/19352747#Series/working_paper_series_national_bureau_of_economic_research> ; # Working paper series (National Bureau of Economic Research) ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/18994426> ;
    schema:name "Costs and Benefits of Prenatal Screening For Cystic Fibrosis"@en ;
    schema:productID "756572045" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/756572045#PublicationEvent/cambridge_mass_national_bureau_of_economic_research_1988> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/19352747#Agent/national_bureau_of_economic_research> ; # National Bureau of Economic Research
    schema:url <http://www.nber.org/papers/w2749> ;
    schema:url <http://papers.nber.org/papers/w2749> ;
    schema:url <http://VH7QX3XE2P.search.serialssolutions.com/?V=1.0&L=VH7QX3XE2P&S=AC_T_B&C=Costs%20and%20Benefits%20of%20Prenatal%20Screening%20For%20Cystic%20Fibrosis&T=marc&tab=BOOKS> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/756572045> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/19352747#Agent/national_bureau_of_economic_research> # National Bureau of Economic Research
    a bgn:Agent ;
    schema:name "National Bureau of Economic Research" ;
    .

<http://experiment.worldcat.org/entity/work/data/19352747#Place/cambridge_mass> # Cambridge, Mass.
    a schema:Place ;
    schema:name "Cambridge, Mass." ;
    .

<http://experiment.worldcat.org/entity/work/data/19352747#Series/nber_working_paper_series> # NBER working paper series ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/756572045> ; # Costs and Benefits of Prenatal Screening For Cystic Fibrosis
    schema:name "NBER working paper series ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/19352747#Series/working_paper_series_national_bureau_of_economic_research> # Working paper series (National Bureau of Economic Research) ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/756572045> ; # Costs and Benefits of Prenatal Screening For Cystic Fibrosis
    schema:name "Working paper series (National Bureau of Economic Research) ;" ;
    .

<http://id.worldcat.org/fast/1075465> # Prenatal diagnosis
    a schema:Intangible ;
    schema:name "Prenatal diagnosis"@en ;
    .

<http://id.worldcat.org/fast/886186> # Cystic fibrosis
    a schema:Intangible ;
    schema:name "Cystic fibrosis"@en ;
    .

<http://viaf.org/viaf/135446122> # National Bureau of Economic Research.
    a schema:Organization ;
    schema:name "National Bureau of Economic Research." ;
    .

<http://viaf.org/viaf/211123975> # Joseph P. Fenerty
    a schema:Person ;
    schema:familyName "Fenerty" ;
    schema:givenName "Joseph P." ;
    schema:name "Joseph P. Fenerty" ;
    .

<http://viaf.org/viaf/38000528> # Alan M. Garber
    a schema:Person ;
    schema:familyName "Garber" ;
    schema:givenName "Alan M." ;
    schema:name "Alan M. Garber" ;
    .

<http://www.worldcat.org/oclc/18994426>
    a schema:CreativeWork ;
    rdfs:label "Costs and benefits of prenatal screening for cystic fibrosis." ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/756572045> ; # Costs and Benefits of Prenatal Screening For Cystic Fibrosis
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.